JPH0253728A - Medicine for prevention of snore - Google Patents
Medicine for prevention of snoreInfo
- Publication number
- JPH0253728A JPH0253728A JP63204242A JP20424288A JPH0253728A JP H0253728 A JPH0253728 A JP H0253728A JP 63204242 A JP63204242 A JP 63204242A JP 20424288 A JP20424288 A JP 20424288A JP H0253728 A JPH0253728 A JP H0253728A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- application
- medicine
- sorbitol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010041235 Snoring Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 6
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 18
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 18
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 210000001989 nasopharynx Anatomy 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 8
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000600 sorbitol Substances 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 239000000443 aerosol Substances 0.000 abstract description 2
- 210000003800 pharynx Anatomy 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 2
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 239000000645 desinfectant Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WTOIRKBUWMPVHG-QMCAAQAGSA-N (2r,3r,4r,5s,6r)-3-amino-2-hexadecyl-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound CCCCCCCCCCCCCCCC[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N WTOIRKBUWMPVHG-QMCAAQAGSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HPJYKMSFRBJOSW-JHSUYXJUSA-N Damsin Chemical compound C[C@H]1CC[C@H]2C(=C)C(=O)O[C@H]2[C@]2(C)C(=O)CC[C@@H]12 HPJYKMSFRBJOSW-JHSUYXJUSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002367 glucuronosyl group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical compound OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（１）利用分野
いびきは単に周囲に迷惑をかけるだけでなく、心筋こう
そくや高血圧とも密接に関係があり、睡眠時無呼吸症の
症候をも呈する。本発明はこのいびきの防止を目的とす
る。DETAILED DESCRIPTION OF THE INVENTION (1) Field of Application Snoring is not only a nuisance to those around you, but is also closely related to myocardial cancer and high blood pressure, and can also be a symptom of sleep apnea. The present invention aims to prevent this snoring.
（２）従来の技術と問題点
フラボノイドを血管保護物質とし、界面活性剤を含む溶
液がいびき防止剤として報告されている。また、グリセ
リンと食塩を含む溶液がいびきの防止に効果があるとさ
れている。しカル、いずれも効果あるいは効果の持続時
間等において十分とはいえない。(2) Prior Art and Problems A solution containing a flavonoid as a blood vessel protective substance and a surfactant has been reported as an anti-snoring agent. Additionally, a solution containing glycerin and salt is said to be effective in preventing snoring. None of these methods can be said to be sufficient in terms of effectiveness or duration of effectiveness.
（３）本発明の詳細
健全な鼻呼吸の阻害はいびきの原因の一つである。鼻粘
膜が乾燥するとその表面が粗荒し空気の流れに乱れを生
じ、息苦しくなり口で呼吸するようになり、軟口蓋が振
動し異常音が発生する。従って鼻腔の粘膜の湿潤が保た
れれば、いびきの原因がとり除がれる。鼻腔の粘膜の乾
燥を防ぐ物質を探索した結果、ンルピトール、ピロリド
ンカルボン酸、およびヒアルロン酸が効果を示すことを
見いだした。(3) Details of the present invention Obstruction of healthy nasal breathing is one of the causes of snoring. When the nasal mucosa becomes dry, its surface becomes rough and airflow becomes turbulent, making it difficult to breathe and forcing the person to breathe through the mouth, which causes the soft palate to vibrate and produce abnormal sounds. Therefore, if the mucous membrane of the nasal cavity is kept moist, the cause of snoring will be eliminated. As a result of searching for substances that prevent the mucous membranes of the nasal cavity from drying out, the researchers found that nlupitol, pyrrolidone carboxylic acid, and hyaluronic acid were effective.
ソルビトールは快い甘味を有する化合物で微生物による
分解も少ない化合物で、多量の水分の保持に効果をもつ
。この化合物は０，０５〜５％、好ましくは０．１〜１
にの水溶液として用いられる。この溶液は、水素イオン
濃度はｐＨ５，０〜７，２．好ましくは６．２〜６．９
に、生理食塩水あるいはクエン酸−リン酸塩などの緩衝
液によって血清と等張に調整されたものが好ましい。Sorbitol is a compound that has a pleasant sweet taste, is not easily decomposed by microorganisms, and is effective in retaining large amounts of water. This compound contains 0.05-5%, preferably 0.1-1
It is used as an aqueous solution. This solution has a hydrogen ion concentration of pH 5.0 to 7.2. Preferably 6.2 to 6.9
Preferably, it is adjusted to be isotonic with serum using a buffer solution such as physiological saline or citrate-phosphate.
ピロリドンカルボン酸もいびきの防止に効果がみられた
。ソルビトールと同様に０．０５〜５％、好ましくは０
．１〜１ｅＸ、水溶液として用いられ、ｐＨが調整され
等張化されたものが好ましい。Pyrrolidone carboxylic acid was also found to be effective in preventing snoring. Like sorbitol, 0.05-5%, preferably 0
．． 1 to 1 eX, preferably used as an aqueous solution and the pH has been adjusted to make it isotonic.
ヒアルロン酸は特に低濃度でいびきの防止に効果がある
。ヒアルロン酸の構成単位であるグルクロノシルＮ−７
セチルーβ−Ｄ−グルコサミン自体も効果を示すが１分
子量数千から数百万のヒアルロン酸にも効果をみる。Hyaluronic acid is particularly effective in preventing snoring at low concentrations. Glucuronosyl N-7, a constituent unit of hyaluronic acid
Cetyl-β-D-glucosamine itself is effective, but hyaluronic acid, which has a molecular weight of several thousand to several million, is also effective.
しかし、高分子量のヒアルロン酸溶液は粘度が高くなり
、高濃度の溶液は粘性が強くなる。従って低〜中分子量
のヒアルロン酸では０．１〜５０００ｍｇ／１０１００
Ｏ，好ましくは１０−３０００ｍｇ１０−３Ｏ００，高
分子量ノヒアルロン酸ハヨり低濃度、すなわち０．１−
３０００ｍｇ／１０１００Ｏ好ましくは１〜１αＸ）ｍ
ｇ／ＩＱＯＯｍｌの溶液が用いられる。低分子量のヒア
ルロン酸は、高分子量のヒアルロン酸の化学的あるいは
酵素的（微生物学的）な部分加水分解物、または生物起
源の低〜中分子量のヒアルロン酸であり１分子量の分布
は必ずしも単一である必要はない。ヒアルロン酸溶液も
有機および無機塩類によって水素イオン濃度が適宜調整
され等張化されたものが好ましい。ヒアルロン酸を有効
成分とする場合は、特に環境との相対湿度の効果を受け
にくいので効果が良好である。However, high molecular weight hyaluronic acid solutions have high viscosity, and highly concentrated solutions have strong viscosity. Therefore, for low to medium molecular weight hyaluronic acid, it is 0.1 to 5000 mg/10100.
O, preferably 10-3000mg 10-3O00, high molecular weight hyaluronic acid, low concentration, i.e. 0.1-
3000mg/10100O preferably 1~1αX)m
A solution of g/IQOOml is used. Low molecular weight hyaluronic acid is a chemical or enzymatic (microbiological) partial hydrolyzate of high molecular weight hyaluronic acid, or low to medium molecular weight hyaluronic acid of biological origin, and the distribution of molecular weight is not necessarily uniform. It doesn't have to be. Preferably, the hyaluronic acid solution is made isotonic by appropriately adjusting the hydrogen ion concentration using organic and inorganic salts. When hyaluronic acid is used as an active ingredient, the effect is particularly good because it is less susceptible to the effects of relative humidity with the environment.
上記の三化合物はそれぞれ単独に有効成分とした場合に
も十分な効果を示すが、それらの複数を有効成分とする
場合に効果は一層増強される。すなわちいびきの抑制効
果の増強と効果の持続時間の延長がみられる。Although each of the above three compounds exhibits sufficient effects when used alone as an active ingredient, the effects are further enhanced when a plurality of them are used as active ingredients. In other words, the snoring suppressing effect is enhanced and the duration of the effect is prolonged.
本薬剤に用いられるヒアルロン酸、ソルビトール、およ
びビロリドンカルボン酸は長期使用に対しても全く無害
であることが証明されてし・るものであり、いかなる副
作用も認められるものでない。The hyaluronic acid, sorbitol, and pyrrolidone carboxylic acid used in this drug have been proven to be completely harmless even with long-term use, and no side effects have been observed.
水剤には上記有効成分のはか１通常用いられる殺菌剤、
防腐剤３例えばアズレン誘導体や界面活性剤を添加し、
より秀れた効果を発揮させることができる。The liquid medicine contains the above active ingredients: 1. A commonly used bactericide,
Preservative 3 For example, add an azulene derivative or a surfactant,
It can bring out better effects.
本発明の薬剤は就寝前、あるいは就寝中にエアゾル、噴
霧器または滴下ピペットなどで鼻腔又は咽頭へ適用する
。適用する量は０１〜２．０ｍｌ程度であるが、適用の
方法、５具、濃度によって相当の範囲がある。The drug of the present invention is applied to the nasal cavity or pharynx using an aerosol, spray, or dropping pipette before or during sleep. The amount to be applied is about 0.1 to 2.0 ml, but there is a considerable range depending on the method of application, the ingredients, and the concentration.
次に示す製剤例は本発明を限定することなしに説明する
ものである。The following formulation examples illustrate the invention without limiting it.
（１）ソルビトール ３．Ｏｇｏ、２
ＭＩＪゾ酸塩と０．１Ｍクエン酸によりｐＨを６．８に
調整した生理食塩水を加えて全量１■◇ｍ１とする。(1) Sorbitol 3. Ogo, 2
Physiological saline adjusted to pH 6.8 with MIJ zoate and 0.1M citric acid is added to make a total volume of 1◇ml.
（２）ピロリドンカルボン酸 １．０ｇソルビ
トール １．０ｇ食塩 ９
．５ｇ
水を加えて全量１０１００Ｏとする。(2) Pyrrolidone carboxylic acid 1.0g Sorbitol 1.0g Salt 9
．． Add 5g of water to make a total volume of 10,100O.
（３）ヒアルロン酸 ５０ｍｇ（平均
分子Ｊ１１００万）
ピロリドンカルボン酸 １，０ｇリン酸塩緩衝
液でｐＨ６，８に調節した生理食塩水を加えて全量１
（Ｘ）Ｏｍ Ｉとする。(3) Hyaluronic acid 50mg (average molecule J11 million) Pyrrolidone carboxylic acid 1.0g Add physiological saline adjusted to pH 6.8 with phosphate buffer to total volume 1
(X) Om I.
（４）ヒアルロン酸 １■（イ）ｍ
ｇ（平均分子量 １０万）
食塩 ９・Ｏｇ
水を加えて １ ｏｏｏｍＩとす
る。(4) Hyaluronic acid 1■(a)m
g (average molecular weight 100,000) Salt 9.0 g Add water to make 1 ooomI.
Claims (2)
１〜１％、ピロリドンカルボン酸を０．０５〜５％、好
ましくは０．１〜１％、ヒアルロン酸を０．１〜５００
０ｐｐｍ好ましくは１〜３０００ｐｐｍ、のいずれかあ
るいは複数を含み、好ましくは有機あるいは無機塩によ
って等張となした水溶液で、鼻咽頭の粘膜に適用するた
めのいびき防止剤。(1) Sorbitol 0.05-5%, preferably 0.05%.
1-1%, pyrrolidone carboxylic acid 0.05-5%, preferably 0.1-1%, hyaluronic acid 0.1-500%.
An anti-snoring agent containing one or more of 0 ppm, preferably 1 to 3000 ppm, and preferably an aqueous solution made isotonic with an organic or inorganic salt, for application to the mucous membrane of the nasopharynx.
加物を加えたいびき防止剤。(2) An anti-snoring agent in which additives such as preservatives, antibacterial surfactants, etc. are added to the above solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63204242A JPH0253728A (en) | 1988-08-17 | 1988-08-17 | Medicine for prevention of snore |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63204242A JPH0253728A (en) | 1988-08-17 | 1988-08-17 | Medicine for prevention of snore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0253728A true JPH0253728A (en) | 1990-02-22 |
Family
ID=16487204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63204242A Pending JPH0253728A (en) | 1988-08-17 | 1988-08-17 | Medicine for prevention of snore |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0253728A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05320055A (en) * | 1991-07-03 | 1993-12-03 | Denki Kagaku Kogyo Kk | Allergy therapeutic agent |
| KR20030063671A (en) * | 2002-01-23 | 2003-07-31 | 주식회사 바이오레인 | Composition for the treatmrent of snoring |
| JP2003535130A (en) * | 2000-06-02 | 2003-11-25 | エルスタン コーポレイション | Control of snoring by oral administration of dimethyl sulfone. |
| FR2859105A1 (en) * | 2003-09-02 | 2005-03-04 | Vegeflore | Composition for treating or preventing snoring, containing mucopolysaccharide, preferably hyaluronic acid, and nonionic surfactant, preferably polysorbate, to improve effectiveness |
| JP2008517041A (en) * | 2004-10-20 | 2008-05-22 | ペルセ メディカ | Snoring prevention composition |
| WO2017022811A1 (en) * | 2015-08-04 | 2017-02-09 | 日東薬品工業株式会社 | Emulsion composition for preventing or ameliorating snoring |
-
1988
- 1988-08-17 JP JP63204242A patent/JPH0253728A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05320055A (en) * | 1991-07-03 | 1993-12-03 | Denki Kagaku Kogyo Kk | Allergy therapeutic agent |
| JP2003535130A (en) * | 2000-06-02 | 2003-11-25 | エルスタン コーポレイション | Control of snoring by oral administration of dimethyl sulfone. |
| KR20030063671A (en) * | 2002-01-23 | 2003-07-31 | 주식회사 바이오레인 | Composition for the treatmrent of snoring |
| FR2859105A1 (en) * | 2003-09-02 | 2005-03-04 | Vegeflore | Composition for treating or preventing snoring, containing mucopolysaccharide, preferably hyaluronic acid, and nonionic surfactant, preferably polysorbate, to improve effectiveness |
| JP2008517041A (en) * | 2004-10-20 | 2008-05-22 | ペルセ メディカ | Snoring prevention composition |
| WO2017022811A1 (en) * | 2015-08-04 | 2017-02-09 | 日東薬品工業株式会社 | Emulsion composition for preventing or ameliorating snoring |
| JPWO2017022811A1 (en) * | 2015-08-04 | 2018-06-14 | 日東薬品工業株式会社 | Emulsion composition for preventing or improving snoring |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4668513A (en) | Method for combating snoring | |
| KR101584824B1 (en) | Osmolyte-containing Preparation for the Treatment of Dry Mucous Membranes | |
| ES2949139T3 (en) | Composition that eliminates nasal congestion and has antiviral activity | |
| ES2318747T3 (en) | COMPOSITIONS OF IMPROVED ANTIMICROBIAL PEROXIDASES. | |
| KR20030082597A (en) | Composition for freshening nostrils and sinus cavities | |
| JP6049624B2 (en) | Oral pharmaceutical film formulation for bitter drugs | |
| JP2013536874A (en) | Nasal spray | |
| KR20210080429A (en) | Sublingual epinephrine composition comprising PH control excipient and penetration enhancer and method of use thereof | |
| CN108743702A (en) | A kind of anti-haze poison spray and preparation method thereof | |
| ES2860098T3 (en) | Composition for nasal application | |
| BRPI9910024B1 (en) | Use of a sugar alcohol mixture containing 6-o-alpha-d-glycopyranosyl-d-sorbitol (1,6-gps) and 1-o-alpha-d-glycopyranosyl-d-mannitol (1,1-gpm) in vitro, and pharmaceutical composition for human or animal consumption | |
| CN111557938A (en) | Disinfectant for quickly damaging viral envelope | |
| US20220110968A1 (en) | Compositions and methods to disinfect, treat and prevent microbial infections | |
| JPH0253728A (en) | Medicine for prevention of snore | |
| CN102861206A (en) | Sterilizing and disinfecting aerosol for skin mucous membrane and preparation method thereof | |
| US5039515A (en) | Mouth cleansing preparation | |
| US4808410A (en) | Pharmaceutical compositions containing dyclonine HC1 and phenol | |
| US20060034947A1 (en) | Erythritol compositions for nasopharynx cleansing | |
| JP2006347958A (en) | Antiinflammatory spray for pharyngeal mucosa | |
| CN105381454B (en) | A kind of nasal cavity wetting agent containing trehalose | |
| CN110151574B (en) | Stable chlorine dioxide gargle and preparation method thereof | |
| CN111388421A (en) | Oral-nasal-throat bi-component spray with antibacterial and antiviral functions and preparation method thereof | |
| US20220008456A1 (en) | Compositions and methods to disinfect, treat and prevent microbial infections | |
| CN113521042A (en) | Alcohol-free wash-free virus inactivation disinfectant special for children and preparation method thereof | |
| CN109512683B (en) | Povidone-iodine composition and preparation method and application thereof |